Compare · BIOT vs JNJ
BIOT vs JNJ
Side-by-side comparison of Biotech Acquisition Company (BIOT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $613.10B, about 48983.3x BIOT ($12.5M).
- Over the past year, BIOT is down 85.8% and JNJ is up 48.3% - JNJ leads by 134.1 points.
- JNJ has been more active in the news (20 items in the past 4 weeks vs 8 for BIOT).
- JNJ has more recent analyst coverage (25 ratings vs 0 for BIOT).
- Company
- Biotech Acquisition Company
- Johnson & Johnson
- Price
- $0.43+0.00%
- $253.77-0.25%
- Market cap
- $12.5M
- $613.10B
- 1M return
- -85.78%
- -2.14%
- 1Y return
- -85.78%
- +48.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 20
- Recent ratings
- 0
- 25
Biotech Acquisition Company
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest BIOT
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets
- SEC Form 20-F filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form CERT filed by Biotech Acquisition Company
- Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Makes Its Nasdaq Debut Under the Ticker “BIOT” on July 24, 2026
- SEC Form 8-A12B filed by Biotech Acquisition Company
- SEC Form 424B3 filed by Biotech Acquisition Company
- SEC Form EFFECT filed by Biotech Acquisition Company
Latest JNJ
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
- Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
- SEC Form 10-Q filed by Johnson & Johnson